Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

The Pistoia Alliance Releases HELM Biomolecular Representation Standard Open Source Tools

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
The Pistoia Alliance is pleased to announce the release of the HELM biomolecular representation standard software toolkit and editor under the permissive open source MIT licence.

HELM (Hierarchical Editing Language for Macromolecules) enables the representation of a wide range of biomolecules (e.g. proteins, nucleotides, antibody drug conjugates) whose size and complexity render existing small-molecule and sequence-based informatics methodologies impractical or unusable. HELM solves this problem through a hierarchical notation that represents complex macromolecules as polymeric structures with support for unnatural components (e.g. unnatural amino acids) and chemical modifications.

The tools released today include:
•    A software toolkit that includes all the functionality needed to implement a HELM-based system.
•    A fully functioning macromolecule editor that enables the drawing of macromolecules and generation of HELM notation.
The technology was originally developed at Pfizer and powers their biomolecule registration system and related toolkit.

According to Sergio Rotstein, a Director in Pfizer’s Research Business Technology organization and Domain Lead for the Pistoia Alliance HELM initiative, “When we started presenting HELM outside of Pfizer, it became obvious that many companies across the industry were facing the same challenges we had faced. By sharing this work in a pre-competitive fashion through the Pistoia Alliance, we are not only helping others to solve this problem but also fostering a technical means by which companies, institutes, CROs, software vendors and IT service providers can exchange biomolecule data and information, which ultimately benefits everyone.”  He added, “It has been truly inspiring to see how 24 different organizations can come together to deliver so successfully on a joint project. Particularly significant contributions have been made by ChemAxon, Bristol-Myers Squibb, GlaxoSmithKline and Roche.”

John Wise, the Pistoia Alliance’s Executive Director, said, “This is an exciting day for the Pistoia Alliance. Macromolecules are increasingly important as therapeutic agents to treat or palliate human disease. By signposting HELM as the standard of choice for the exchange of macromolecule information in an increasingly externalized R&D environment, and by providing effective tools for groups to work with that standard, the Pistoia Alliance makes another contribution to lowering the barriers to innovation in life science R&D.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
New Centre Offers Ultra-Speed Protein Analysis
UW-Madison researchers to establish development centre for next-gen protein measurement technologies.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
Biomarker for Parkinson's Disease Found in Urine Samples
Protein identified as Parkinson's biomarker sourced from patient's stored frozen urine samples.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!